Journal Title：Pediatric Drugs

Pediatric Drugs promotes the optimization and advancement of all aspects of pharmacotherapy for healthcare professionals interested in pediatric drug therapy (including vaccines). The program of review and original research articles provides healthcare decision makers with clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents. The Journal includes:

-overviews of contentious or emerging issues.

-comprehensive narrative reviews of topics relating to the effective and safe management of drug therapy through all stages of pediatric development.

-practical reviews covering optimum drug management of specific clinical situations.

-systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.

-Adis Drug Reviews of the properties and place in therapy of both newer and established drugs in the pediatric population.

-original research articles reporting the results of well-designed studies with a strong link to clinical practice, such as clinical pharmacodynamic and pharmacokinetic studies, clinical trials, meta-analyses, outcomes research, and pharmacoeconomic and pharmacoepidemiological studies.

Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Pediatric Drugs may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand important medical advances.

《兒科藥物》致力于為對兒科藥物治療（包括疫苗）感興趣的醫療保健專業人士促進藥物治療各個方面的優化和進步。評論和原創研究文章計劃為醫療保健決策者提供有關新生兒學和兒童及青少年護理所有領域藥物治療相關問題的臨床適用知識。該期刊包括：

-有爭議或新興問題的概述。

-全面敘述與兒科發展各個階段藥物治療的有效和安全管理有關的主題。

-實用評論，涵蓋特定臨床情況的最佳藥物管理。

-系統評論，使用 PRISMA 聲明概述的明確、系統方法，匯總經驗證據以回答特定研究問題。

-Adis 藥物評論，評論兒科人群中新藥和成熟藥物的特性和治療地位。

-原創研究文章，報告精心設計的研究結果，與臨床實踐密切相關，例如臨床藥效學和藥代動力學研究、臨床試驗、薈萃分析、結果研究以及藥物經濟學和藥物流行病學研究。

其他數字功能（包括動畫摘要、視頻可以隨文章發布摘要、幻燈片、音頻幻燈片、教學視頻、信息圖表、播客和動畫等內容；這些內容旨在提高期刊內容的知名度、讀者群和教育價值。此外，在《兒科藥物》上發表的文章可能會附有通俗易懂的摘要，以幫助對該領域有一定了解但不具備深入專業知識的讀者了解重要的醫學進展。

Pediatric Drugs創刊于1999年，由Springer International Publishing出版商出版，收稿方向涵蓋PEDIATRICS - PHARMACOLOGY & PHARMACY全領域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業認可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12周，或約稿 ，影響因子指數3.4，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。